Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A fifth of the worldwide population with fatty liver disease consists of lean people.
Hepatitis A and B can be prevented with vaccines, and hepatitis C can be cured with antiviral treatment.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
Exercising for a longer period of time was especially linked to a reduced risk of death from cardiovascular conditions.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
However, people with cirrhosis alone were as likely to die as those with both cirrhosis and COVID-19.
Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
The World Health Organization coordinates efforts to create flu and COVID-19 vaccines and to fight other global health issues.
The immunotherapy and targeted therapy combo improved both overall survival and patient-reported outcomes.
Men who have sex with men on PrEP are also diagnosed with hepatitis C at a substantially elevated rate.
Researchers found that overconsumption of fructose overburdened the small intestine, leading to fatty liver disease.
The CDC recently expanded its hepatitis A vaccine recommendation and now advises it for all people with HIV older than 12 months.
Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.